BACK TO SCHOOL: Communicating with the Team
Guest blog by Celeste Graham, PT, ex-Director of Physical Therapy, CureDuchenne CaresUPDATED 8/12/2022 We are at that time of year when the shelves of our local superstores that just recently […]
Guest blog by Celeste Graham, PT, ex-Director of Physical Therapy, CureDuchenne CaresUPDATED 8/12/2022 We are at that time of year when the shelves of our local superstores that just recently […]
Guest blog by Hawken Miller For those with Duchenne Muscular Dystrophy the experience and education of a four-year university is likely within your grasp, and being away from home […]
Today, we are very pleased to announce that Pfizer has acquired Bamboo Therapeutics, a gene therapy company we invested in earlier this year through CureDuchenne Ventures. The deal is valued […]
The announcement that PTC recently submitted an appeal to elevate the “Refusal to File” of Translarna (also known as ataluren and PTC124) to the next level of FDA management is […]
Guest blog by Hawken Miller Many of the things I don’t think are possible for me to do really are. Once I get over my initial apprehension and thoughts […]
BioMarin is providing a further update to the Duchenne Community following our announcement of the withdrawal of the EMA marketing application and discontinuation of clinical and regulatory development of […]
We are sharing the following update from Sarepta Therapeutics. Sarepta Therapeutics is updating the Duchenne community regarding recent changes to the Phase III confirmatory clinical study, ESSENCE (Study […]
From Paul Miller Another Father’s Day is here and I wish you all a meaningful day filled with memories that will last a lifetime. As I think about the most […]
BioMarin is providing a further update to the Duchenne Community in light of recent announcements of withdrawal of the EMA marketing application and discontinuation of clinical and regulatory development […]